A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate

Rivero-Juarez, A.; López-Cortés, L.F.; Camacho, A.; Mira, J.A.; Téllez, F.; Marquez, M.; Merino, D.; Pineda, J.A.; Rivero, A.

Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America 58(1): 130-133


ISSN/ISBN: 1537-6591
PMID: 24065317
DOI: 10.1093/cid/cit653
Accession: 051055731

Download citation:  

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

We designed a study to evaluate the efficacy of a 24-week treatment strategy in HIV/hepatitis C virus (HCV) genotype 3-coinfected patients achieving rapid virologic response for a first HCV treatment with pegylated interferon plus ribavirin (peg-IFN/RBV). Our results suggest that a shorter course of peg-IFN/RBV therapy may be sufficient in this population.